Although the predictive and prognostic utilization of EGFR remains to be adequately defined, it has been reported that patients with GBM treated with temozolomide that had EGFR amplification, maintenance of PTEN, and wild-type p53 and p16 were strong prognostic indicators of overall survival [11]. Here, TP53 is linked to glioblastoma.